Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Rubius Therapeutics, Inc. (RUBY) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/09/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
Docs: "Rubius Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update Presented Updated Clinical Data from Monotherapy Phase 1 Arm of RTX-240 Clinical Trial in Advanced Solid Tumors, Showing Clinical Responses with Favorable Tolerability in PD-1 Refractory Disease Expanded Ongoing Phase 1 Arm of RTX-240 + Pembrolizumab to Focus on Non-Small Cell Lung Cancer and Renal Cell Carcinoma Dosing Patients in Phase 1 Clinical Trial of RTX-224 in Select Solid Tumors; Initial Results Expected 4Q’ 22 or 1Q’ 23 Successfully Scaled Manufacturing to 200L Bioreactors Company Provides Update on Phase 1 Clinical Trial of RTX-321 in Advanced Human Papilloma Virus 16-Positive Cancers CAMBRIDGE, Mass., May 10, 2022 -- Rubius Therapeutics, Inc. , a clinical-stage biopharmaceutical compan..."
11/08/2021 8-K Quarterly results
Docs: "Rubius Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update U.S. Food and Drug Administration Clears Investigational New Drug Application for RTX-224, Rubius’ Third Oncology Candidate Clinical Results Expected by Year-End or First Quarter 2022 in Phase 1 Trials of Single-Agent RTX-240 in Advanced Solid Tumors and Relapsed/Refractory Acute Myeloid Leukemia Laurence “Larry” Turka, M.D., Promoted to Head of Research & Translational Medicine CAMBRIDGE Mass., November 8, 2021 -- Rubius Therapeutics, Inc. , a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today reported third quar..."
05/10/2021 8-K Quarterly results
11/09/2020 8-K Quarterly results
Docs: "Rubius Therapeutics Reports Third Quarter 2020 Financial Results and Strong Execution Across the Pipeline Completed Dosing of Fourth Cohort in RTX-240 Phase 1/2 Solid Tumor Clinical Trial Dosed First Patient in RTX-240 Phase 1 Relapsed/Refractory Acute Myeloid Leukemia Clinical Trial Filed Investigational New Drug Application with U.S. Food and Drug Administration for RTX-321 for Human Papillomavirus 16-Positive Cancers with Frozen Drug Substance CAMBRIDGE, Mass., November 9, 2020 -- Rubius Therapeutics, Inc. , a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today reported third quarter 2020 financial results and provided an overview of operational progress...."
08/10/2020 8-K Quarterly results
05/11/2020 8-K Quarterly results
Docs: "Rubius Therapeutics Reports First Quarter 2020 Financial Results and Provides Operational Update Completed Strategic Reprioritization of Pipeline to Focus on Oncology and Autoimmunity Dosed First Patient in Phase 1/2 Clinical Trial of RTX-240 for Advanced Solid Tumors Successfully Produced cGMP Clinical Supply of RTX-240 from Fully Owned Manufacturing Facility Strong Cash Position Cambridge, Mass., May 11, 2020 -- Rubius Therapeutics, Inc. , a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today reported first quarter 2020 financial results and provided an overview of operational progress. “During the first quarter, we made significant progress in advancing our business by reprioritizing our th..."
03/12/2020 8-K Quarterly results
Docs: "Rubius Therapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results and Announces Strategic Focus on Oncology and Autoimmunity RTX-240 Investigational New Drug Application for Solid Tumors Cleared by U.S. FDA"
11/14/2019 8-K Quarterly results
08/13/2019 8-K Quarterly results
05/15/2019 8-K Quarterly results
Docs: "Rubius Therapeutics Reports First Quarter 2019 Financial Results and Operational Progress Enrollment for Phase 1b Trial of RTX-134 for Phenylketonuria on Track for Second Quarter 2019; Initial Clinical Data Anticipated in Second Half 2019"
11/13/2018 8-K Quarterly results
Docs: "Rubius Therapeutics Reports Third Quarter 2018 Financial Results and Operational Progress"
08/31/2018 8-K Quarterly results
Docs: "Rubius Therapeutics Reports Second Quarter 2018 Financial Results"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy